Metabolic Syndrome Reduces Long-term Survival In Colorectal Cancer Patients without affecting postoperative complications: A Propensity Score-matched Analysis

Purpose: Metabolic syndrome (MetS) is associated with poor prognosis in many cancers. However, few studies have comprehensively analyzed the relationship between metabolic syndrome and the overall survival of colorectal cancer (CRC) patients. Our study aimed to comprehensively analyze whether MetS could affect postoperative complications and long-term survival in patients with CRC. Patients and methods We included patients who underwent colorectal cancer resection at our center between January 2016 and December 2018 for this analysis. The propensity score matching analysis was performed to reduce the bias. Dividing CRC patients into MetS and Non-MetS groups based on whether they had MetS. Univariate and multivariate analyses were used to identify the risk factors affecting overall survival (OS). Results: : A total of 268 patients were included in the study, of whom 120 patients were included for further analysis after propensity score matching. No significant differences were found in Clinicopathological features between the MetS group and Non-MetS group after matching. Patients with MetS had a shorter OS compared with non-MetS (P=0.027), however the postoperative complications were not significantly different between them. In multivariate analysis, We found MetS (hazard ratio [HR]=1.997, P=0.042), tumor-node-metastasis (TNM) stage (HR=2.422, P=0.003), and intestinal obstruction (HR=2.761, P=0.010) were independent risk factors for OS. Conclusion: Metabolic syndrome affects long-term survival of CRC patients without affecting postoperative complications.